2020
Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy
Liu C, Cheng H, Jin K, Fan Z, Gong Y, Qian Y, Deng S, Huang Q, Ni Q, Yu X, Luo G. Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy. Cancer Control 2020, 27: 1073274820915947. PMID: 32268796, PMCID: PMC7153189, DOI: 10.1177/1073274820915947.Peer-Reviewed Original ResearchMeSH KeywordsChemotherapy, AdjuvantDeoxycytidineDrug Resistance, NeoplasmFemaleGemcitabineHumansLymph NodesLymphatic MetastasisMaleMiddle AgedPancreatic NeoplasmsConceptsGemcitabine-based adjuvant chemotherapyResectable pancreatic cancerPancreatic cancerAdjuvant chemotherapyN2 node involvementNode involvementCurative resection of pancreatic adenocarcinomaResection of pancreatic adenocarcinomaGemcitabine-based regimenGemcitabine-based treatmentNode-positive subgroupEfficacy of gemcitabineGemcitabine-based chemotherapyN2 tumorsAdjuvant regimenNodal involvementNodal statusNode-negativeCurative resectionPancreatic adenocarcinomaSubgroup patientsLymphatic metastasisChemotherapyPatientsCancer
2016
The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer
Guo M, Luo G, Liu C, Cheng H, Lu Y, Jin K, Liu Z, Long J, Liu L, Xu J, Huang D, Ni Q, Yu X. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. International Journal Of Molecular Sciences 2016, 17: 1090. PMID: 27399694, PMCID: PMC4964466, DOI: 10.3390/ijms17071090.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntigens, Tumor-Associated, CarbohydrateCarcinoma, Pancreatic DuctalChemotherapy, AdjuvantDisease-Free SurvivalErbB ReceptorsFemaleHumansImmunohistochemistryKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedMultivariate AnalysisPancreatic NeoplasmsPredictive Value of TestsPrognosisProportional Hazards ModelsRetrospective StudiesConceptsAdjuvant chemotherapyPostoperative survivalEGFR statusOverall survivalSurvival benefitEGFR expressionPancreatic cancerProlonged median overall survivalResected pancreatic cancer patientsAssociated with improved survivalSurgically resected pancreatic cancerMedian overall survivalResectable pancreatic cancerSignificant survival benefitEpidermal growth factor receptorKaplan-Meier analysisPancreatic cancer patientsPancreatic cancer treatmentStudies of EGFRGrowth factor receptorResectable PDACAdjuvant therapyPrognostic significanceImproved survivalExpression subgroupsWhich patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer?
Liu C, Lu Y, Luo G, Cheng H, Guo M, Liu Z, Xu J, Long J, Liu L, Fu D, Ni Q, Li M, Yu X. Which patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer? Oncotarget 2016, 7: 29177-29186. PMID: 27081079, PMCID: PMC5045387, DOI: 10.18632/oncotarget.8690.Peer-Reviewed Original ResearchConceptsPancreatic head cancerResectable pancreatic head cancerLymph node ratioHead cancerLymph nodesTumor locationPara-aortic lymph node dissectionPara-aortic lymph node metastasisPara-aortic lymph nodesCurative surgical resectionLymph node dissectionIndependent prognostic factorLymph node metastasisPoor surgical outcomesDuctal adenocarcinoma patientsPoor prognostic markerPreoperative serum CA125Curative pancreaticoduodenectomyNode dissectionPancreatic headRadical surgerySurgical resectionNode metastasisPrognostic factorsSuch patients
2015
Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer
Liu Z, Luo G, Guo M, Jin K, Xiao Z, Liu L, Liu C, Xu J, Ni Q, Long J, Yu X. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. Pancreatology 2015, 15: 253-258. PMID: 25921232, DOI: 10.1016/j.pan.2015.03.012.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapy, AdjuvantDeoxycytidineFemaleHumansLymph NodesLymphatic MetastasisMaleMiddle AgedPancreatectomyPancreatic NeoplasmsRetrospective StudiesSurvival AnalysisTreatment OutcomeConceptsAdjuvant chemoradiotherapyLymph node statusNode statusPancreatic cancerPancreatic adenocarcinomaDifferent lymph node statusCurative R0 resectionEffect of chemoradiotherapyImproved median OSLN-negative diseaseLN-positive diseaseRole of lymphOverall median survivalMedian OSAdjuvant therapyR0 resectionMedian survivalPositive diseaseNegative diseaseChemoradiotherapyPatientsMultivariate analysisDiseaseLymphAdenocarcinoma
2009
Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland
Vila L, Liu H, Al-Quran S, Coco D, Dong H, Liu C. Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Modern Pathology 2009, 22: 1296-1302. PMID: 19617878, PMCID: PMC3746033, DOI: 10.1038/modpathol.2009.95.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Adenoid CysticDNA Mutational AnalysisExonsFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryLymphatic MetastasisMaleMiddle AgedMutation, MissensePoint MutationPolymerase Chain ReactionProto-Oncogene Proteins c-kitSalivary Gland Neoplasms